Biogen Exercises its Option with Genentech to Develop and Commercialize Mosunetuzumab for B-Cell Non-Hodgkin’s Lymphoma
Shots:
- Genentech to receive a $30M one-time option fee on Abs targeting CD20 & is eligible to receive the development expenses of the product incurred during 2021 while Biogen is eligible to receive royalties on sales outside the US & will share the profits and losses of mosunetuzumab in the US
- Biogen gets the joint decision-making rights for the development and commercialization of mosunetuzumab and Genentech will be responsible to lead the strategy and implementation of the program
- Genentech is planning to complete a BLA submission for approval of mosunetuzumab in the (GO29781) study for patients with R/R FL. If approved, the therapy will be the 1st CD20xCD3 T-cell engaging bispecific Ab in NHL
Ref: Biogen | Image: Biogen
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
